SOTIO Biotech, a clinical stage immuno-oncology company, entered an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc., a biotechnology company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs) with an excellent therapeutic index. SOTIO will obtain rights to use LCB’s ADC technology for up to five therapeutic programs targeting distinct tumor-associated antigens.   SOTIO will combine its antibodies with LCB...